Cargando…

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury

Our objective was to assess the incidence of drug bioaccumulation in critically ill COVID-19 patients with AKI receiving intermediate dose nadroparin for thrombosis prophylaxis. We conducted a Prospective cohort study of critically ill COVID-19 patients. In patients on intermediate dose nadroparin (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eck, R. J., van de Leur, J. J. C. M., Wiersema, R., Cox, E. G. M., Bult, W., Spanjersberg, A. J., van der Horst, I. C. C., Lukens, M. V., Gans, R. O. B., Meijer, K., Keus, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579123/ https://www.ncbi.nlm.nih.gov/pubmed/36257974 http://dx.doi.org/10.1038/s41598-022-21560-2

Ejemplares similares

The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
por: Mast, L., et al.
Publicado: (2023)

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022)

Low Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis
por: Eck, Ruben J., et al.
Publicado: (2019)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis
por: Eck, Ruben J, et al.
Publicado: (2022)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients: data from two prospective cohort studies
por: Eck, Ruben J., et al.
Publicado: (2021)

Different applications of the KDIGO criteria for AKI lead to different incidences in critically ill patients: a post hoc analysis from the prospective observational SICS-II study
por: Wiersema, Renske, et al.
Publicado: (2020)

Burden of acute kidney injury and 90-day mortality in critically ill patients
por: Wiersema, Renske, et al.
Publicado: (2019)

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
por: Horinaka, Shigeo, et al.
Publicado: (2017)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series
por: Russcher, Marije, et al.
Publicado: (2013)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

Clinical examination findings as predictors of acute kidney injury in critically ill patients
por: Wiersema, Renske, et al.
Publicado: (2019)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

Clinical examination for diagnosing circulatory shock
por: Hiemstra, Bart, et al.
Publicado: (2017)

Nadroparin calcium: Spontaneous retroperitoneal bleeding: 2 case reports
Publicado: (2022)

Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
por: Diepstraten, Jeroen, et al.
Publicado: (2022)

Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models
por: Zhuang, Xibing, et al.
Publicado: (2018)

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
por: Groen, Harry J. M., et al.
Publicado: (2019)

Clinical Examination for the Prediction of Mortality in the Critically Ill: The Simple Intensive Care Studies-I
por: Hiemstra, Bart, et al.
Publicado: (2019)

Evaluation of clotrimazole prophylaxis on tacrolimus trough concentrations in kidney transplant recipients
por: Wings, Emily, et al.
Publicado: (2022)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
por: Debergh, I, et al.
Publicado: (2010)

Associations between tricuspid annular plane systolic excursion to reflect right ventricular function and acute kidney injury in critically ill patients: a SICS-I sub-study
por: Wiersema, Renske, et al.
Publicado: (2019)

Clinical examination, critical care ultrasonography and outcomes in the critically ill: cohort profile of the Simple Intensive Care Studies-I
por: Hiemstra, Bart, et al.
Publicado: (2017)

Should the ultrasound probe replace your stethoscope? A SICS-I sub-study comparing lung ultrasound and pulmonary auscultation in the critically ill
por: Cox, Eline G. M., et al.
Publicado: (2020)

The effect of inflammation on voriconazole trough concentrations in children
por: ter Avest, Mendy, et al.
Publicado: (2016)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Bundled care in acute kidney injury in critically ill patients, a before-after educational intervention study
por: Koeze, Jacqueline, et al.
Publicado: (2020)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study
por: Jochberger, Stefan, et al.
Publicado: (2005)

Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tkpkqo76ujdqg36824292n3jso